Mentice receives order of total SEK 7.0 million from Edwards Lifesciences
Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, receives order from Edwards Lifesciences for the segment Medical Device Industry relating to solutions for the Mitral/Tricuspid Valve therapy areas. The order covers system sales and development to be delivered during the fourth quarter 2020. The total order value amounts to SEK 7.0 million and will be accounted for in the order book for the third quarter 2020.
Mentice receives order from Edwards Lifesciences (EW) (Irvine, CA) relating to development and systems providing training solutions to support EW in safe roll-out of medical device solutions for the mitral and tricuspid valve therapy areas.
The order will be accounted for in the order book for the segment Medical Device Industry during the third quarter 2020. The total value for the order amounts to SEK 7.0 million to be delivered during the fourth quarter 2020.
For more information, please contact:
Göran Malmberg, CEO, Mentice
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22
This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, at 10.00 on July 16, 2020.
Marketplace| Nasdaq First North Premier, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399